MTM Laboratories Overview

  • Founded
  • 1999
Founded
  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A
  • Latest Deal Amount
  • $274M
Latest Deal Amount

MTM Laboratories General Information

Description

Developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. The company markets its proprietary CINtec(R) Histology Kit and CINtec(R) Cytology Kit as adjunct tools for the early detection and diagnosis of cervical cancer.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Diagnostic Equipment
Other Industries
Monitoring Equipment
Therapeutic Devices
Acquirer
Primary Office
  • BioPark
  • Im Neuenheimer Feld 583
  • 69120 Heidelberg
  • Germany
+49 06221 000000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

MTM Laboratories Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Merger/Acquisition 31-Aug-2011 $274M 00000 00000 Completed Generating Revenue
4. Later Stage VC (Series C) 08-Nov-2010 000.00 00000 Completed Generating Revenue
3. Later Stage VC (Series C) 09-Oct-2006 000.00 000.00 Completed Product Development
2. Later Stage VC (Series B) 21-May-2003 $13.6M $15.4M Completed Generating Revenue
1. Early Stage VC (Series A) 01-Jan-1999 $1.76M $1.76M Completed Product Development
To view MTM Laboratories’s complete valuation and funding history, request access »

MTM Laboratories Patents

MTM Laboratories Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-7662595-B2 Using mutation in microsatellite sequences and 3'-untranslated sequences of caspase 2 (casp2) gene as diagnostic/prognostic tools in detection of cell proliferative disorders Active 19-Oct-2004 0000000000 0
US-20080096197-A1 Using mutation in microsatellite sequences and 3'-untranslated sequences of caspase 2 (casp2) gene as diagnostic/prognostic tools in detection of cell proliferative disorders Granted 19-Oct-2004 0000000000
ES-2337573-T3 Compounds and procedures for estimating the state of microsatelites instability (msi). Active 19-Oct-2004 0000000000
DE-602004024540-D1 Compositions and methods for the determination of Active 19-Oct-2004 0000000000
EP-1650311-B1 Compounds and methods for assessment of microsatellite instability (msi) status Active 19-Oct-2004 C12Q1/6886
To view MTM Laboratories’s complete patent history, request access »

MTM Laboratories Executive Team (5)

Name Title Board Seat Contact Info
Douglas Pretsell Director, Accounting
Jan Wauters Director, Sales
You’re viewing 2 of 5 executive team members. Get the full list »

MTM Laboratories Board Members (6)

Name Representing Role Since
Ruediger Ridder Ph.D Self Chief Scientific Officer & Board Member 000 0000
You’re viewing 1 of 6 board members. Get the full list »

MTM Laboratories Former Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Gilde Healthcare Partners Venture Capital Minority 000 0000 000000 0
HBM Healthcare Investments Venture Capital Minority 000 0000 000000 0
HBM Partners Venture Capital Minority 000 0000 000000 0
Hatteras Venture Partners Venture Capital Minority 000 0000 000000 0
Heidelberg Innovation Fonds Management Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »